Mar 27,2023

Dario Selected as Digital Therapeutics Partner by a Top-Ten Digitally Enabled Pharmacy Benefits Manager

DarioHealth Corp., a global leader in digital therapeutics, has secured a contract with a top-ten digitally enabled Pharmacy Benefits Manager (PBM) to provide its digital therapeutics, starting with the diabetes solution to employer clients beginning in the second quarter of 2023. This milestone achievement is the result of Dario's strategic partnership with Sanofi U.S. The PBM will replace its existing digital diabetes solution with Dario's proven cardio metabolic digital therapeutic, expanding its roster of digital health solutions. The partnership signifies Dario's focus on building strong collaborations with leading healthcare companies to accelerate the adoption of its solutions in the employer and payer markets

COLLABORATION PARTNERSHIP

#institution

#coaching

View Analyst & Ambassador Comments
Go to original news
Mar 22,2023

Dario Announces Strategic Partnership with Amwell to Expand Access to its Cardiometabolic Digital Therapeutic Solution

DarioHealth Corp. has announced a strategic partnership with Amwell, a digital healthcare enablement leader, to deliver its cardiometabolic digital therapeutic solution to Amwell customers starting in the second half of 2023. The partnership aims to accelerate the adoption of Dario's solutions by making its proven and highly personalized digital solution available to Amwell's comprehensive portfolio of care solutions and affiliated clinicians. Members living with cardiometabolic health concerns such as diabetes, high blood pressure, and weight management challenges will have access to Dario's digital solution to better manage their conditions and improve outcomes between visits with clinicians practicing on the Amwell platform

COLLABORATION PARTNERSHIP

#institution

#telehealth

#mobile app

View Analyst & Ambassador Comments
Go to original news
Mar 21,2023

AT&T Joins MyndVR's DigitalTherapyNow.org as Coalition Supporter to Promote Passage of Digital Therapeutics Bill

MyndVR, the provider of therapeutic VR experiences designed for the aging population, today announced AT&T's support of the DigitalTherapyNow.org initiative. This purpose-driven alliance of academic and industry partners was designed to educate lawmakers in the effort to pass the bipartisan Access to Prescription Digital Therapeutics Act of 2023. AT&T stands alongside other industry leaders supporting this effort, including the XR Association (XRA), HTC, Select Rehabilitation, International VR Healthcare Association (IVRHA), and the National Association of State Veteran Homes (NASVH). The bipartisan legislation, proposed by Reps. Mike Thompson (CA-05) and Kevin Hern (OK-01) and Sens. Jeanne Shaheen (D-NH) and Shelley Moore Capito (R-WV), aims to officially define prescription digital therapeutics (PDTx) at the federal level and establish new payor benefits to treat a broad range of age-related health conditions. The bill was reintroduced on March 7, 2023.

COLLABORATION PARTNERSHIP

#institution

#virtual reality

View Analyst & Ambassador Comments
Go to original news
Mar 08,2023

Startek Offers Mental Health Support App to New Mothers Through the Partnerships with Curio Digital Therapeiutics

Curio Digital Therapeutics has partnered with Global customer experience solutions provider Startek to provide postpartum mental health support to its US-based associates. The partnership aims to foster wellbeing for new mothers, who often suffer from depression in the months following childbirth. Startek will offer MamaLift, through the Curio platform, which offers digitized therapy content through augmented reality, meditations, and interactive exercises

COLLABORATION PARTNERSHIP

#institution

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jun 08,2023 TOP STORY

Owkin launches PortrAIt, in collaboration with Gustave Roussy

The PortrAIt Consortium, which brings together different public and specialized private AI and oncology operators, aims to turn France into a global leader in the use of AI to diagnose and treat diseases. Created in July 2022, the project was officially unveiled in late March 2023. Over the next five years, PortrAIt aims to create at least 15 AI tools for digital pathology, which may speed up pathologists’ work, detect the presence of certain biomarkers, and predict patient outcomes. PortrAIt will be broken down in two phases. Initially, a platform, PortrAIt Lab, will be created as early as July 2023. “Pathologists will have a role to play in developing diagnostic tools by annotating slides, for example, to train AI models,” said Etienne Hatton, Consortium project manager. Then, a second distribution platform will function a bit like a market place. This platform will be managed by Tribun Health and Owkin, and will act as a reliable resource for all operators involved in the sector, with the aim of creating a digital pathology channel.

COLLABORATION PARTNERSHIP

#institution

#ai/software

View Analyst & Ambassador Comments
Go to original news
Jun 02,2023

Precision Cancer Consortium Teams Up with Massive Bio to Utilize AI Analytics and Enhance Clinical Trial Matching for Cancer Patients Worldwide

Massive Bio, a leading artificial intelligence (AI) analytics company specializing in precision oncology, has been selected by the Precision Cancer Consortium (PCC), a collaboration of several global biopharmaceutical companies, to optimize clinical trial matching through their innovative AI analytics tools. PCC was established in 2022 with a shared vision of enabling access to comprehensive testing for all cancer patients globally, and is currently comprised of AstraZeneca, Bayer, Eli Lilly & Company, GSK, Johnson & Johnson/Janssen, Novartis, and Roche. The partnership will incorporate PCC member clinical trial protocols and patient inclusion and exclusion criteria into existing machine learning matching algorithms in SYNERGY-AI leveraged within Massive Bio’s Deep Learning Clinical Trial Matching System (DLCTMS). This will optimize the quality and efficiency of matching patients to trials across sponsor programs and improve patient access to targeted Next Generation Sequencing (NGS) testing and tailored interventions.

COLLABORATION PARTNERSHIP

#institution

#ai/software

#rwd

View Analyst & Ambassador Comments
Go to original news
Jun 03,2023 TOP STORY

Massive Bio and The Oncology Institute (TOI) Forge Partnership to Revolutionize Cancer Care and AI-enabled Cancer Research

Massive Bio, a leader in leveraging artificial intelligence and concierge services to empower cancer patients, announced a non-exclusive partnership with The Oncology Institute (TOI), a premier provider of cutting-edge cancer care. Under this visionary collaboration, Massive Bio will support TOI with evaluating the eligibility of patients for TOI’s active clinical trial portfolio, utilizing their cooperative business model driven by AI and precision medicine. By leveraging sophisticated algorithms and comprehensive diagnostic information, Massive Bio will empower patients and ordering physicians at TOI with clinical decision-support and clinical trial matching services. Furthermore, this collaboration will expand the scope of cancer research through Massive Bio’s recent ChatGPT-powered chatbots for oncology research release during ASCO 2023.

COLLABORATION PARTNERSHIP

#institution

#ai/software

#chatbot

View Analyst & Ambassador Comments
Go to original news
Jun 05,2023

Aster Insights announces that The University of Kansas Cancer Center will join the Oncology Research Information Network (ORIEN)

Aster Insights (formerly known as M2GEN), the leading provider of technology-enabled data and analytics solutions for oncology discovery, today announced The University of Kansas Cancer Center will join its Oncology Research Information Exchange Network (ORIEN). The KU Cancer Center will be the latest NCI-designated cancer center to join ORIEN, which is comprised of 18 cancer centers across the U.S. dedicated to collaborative research to accelerate cancer discovery and development. Launched in 2014, ORIEN is the largest and longest-running academic cancer research consortium of its kind in the United States. ORIEN members participate in the Total Cancer Care (TCC) protocol, the largest lifetime-consented patient research program in oncology, utilizing deep clinical and genomic data to best support patient care, research, and discovery.

COLLABORATION PARTNERSHIP

#institution

#rwd

View Analyst & Ambassador Comments
Go to original news
May 31,2023

InHealth partners with Qure.ai to enhance quality of Telereporting services with AI-powered chest X-ray solution

InHealth, the UK’s largest specialist provider of diagnostic and healthcare solutions, has announced a partnership with Qure.ai, a market leader in medical artificial intelligence (AI) solutions. Through this partnership, InHealth will be deploying Qure.ai‘s AI solution to aid in the classification of chest X-rays into normal and abnormal exams. The solution will be deployed across InHealth’s entire Tele-reporting service arm to help enhance the quality and accuracy of reporting using AI. Qure.ai‘s chest X-ray software can detect multiple lung abnormalities in under one minute. It can accurately assess radiological findings presumptive of a host of lung diseases, including lung cancer, pneumonia, COPD, TB, and heart failure, among others.

COLLABORATION PARTNERSHIP

#institution

#ai/software

#telehealth

View Analyst & Ambassador Comments
Go to original news
Apr 21,2023

Welby Establishes “Oncology PHR Consortium” and Starts Joint Project for Clinical Implementation of PHR with National Cancer Center Hospital

Welby Co., Ltd. aims to realize patient-centered cancer treatment and improve treatment outcomes through PHR (Personal Health Record). In addition, as an initiative of the “Oncology PHR Consortium”, Welby has started a joint project with the National Cancer Center and other cancer treatment hospitals. The 4th Basic Plan for the Promotion of Cancer Control, which will start this fiscal year, calls for the promotion of digitalization as a foundation to support cancer prevention, cancer treatment, and coexistence with cancer.

COLLABORATION PARTNERSHIP

#institution

#rpm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Subscribe to INSTITUTION